Clinical Trials Logo

Clinical Trial Summary

This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the overall response rate after 8 cycles of treatment according to the International Myeloma Working Group Criteria (IMWG). SECONDARY OBJECTIVES: I. To determine time to progression to multiple myeloma (TTP) at 30 months from study entry. II. To determine overall survival (OS). III. To determine duration of response (DOR). IV. To determine the clinical benefit rate (CBR) after 8 cycles of treatment according to the modified IMWG Criteria for multiple myeloma (MM). V. To evaluate safety and tolerability of single agent treatment in this population. EXPLORATORY OBJECTIVES: I. Rate of minimal residual disease (MRD) negativity at complete remission (CR). II. Molecular profiling (including whole exome sequencing and gene expression profiling) and cellular (including flow cytometry) profiling at baseline and/or at progression using bone marrow aspirate samples and peripheral blood. III. Immunophenotypic characterization of dendritic, T-, B-, natural killer (NK)- and natural killer T (NKT)-cells, and inhibitory/activation markers on tumor cells at baseline and at completion of 8 cycles of therapy in bone marrow aspirate samples and/or peripheral blood. IV. Evaluation of changes in PD-L1 and PD-1 expression at baseline/end of 8 cycles of treatment and correlate with clinical response. OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6-12 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02603887
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase Early Phase 1
Start date July 20, 2016
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03937635 - Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma Phase 3
Active, not recruiting NCT04370483 - Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma Early Phase 1
Terminated NCT02353572 - Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05014646 - Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients Phase 2
Active, not recruiting NCT05288062 - Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma Phase 2
Recruiting NCT05136807 - Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
Recruiting NCT05312255 - Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma N/A
Active, not recruiting NCT02960555 - Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) Phase 2
Active, not recruiting NCT03631043 - Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma Early Phase 1
Recruiting NCT02726750 - Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Withdrawn NCT03952832 - Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma Phase 2
Recruiting NCT04776395 - Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma Phase 2
Completed NCT02492750 - Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Phase 1